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Abstract
Background: Health-related quality of life (HR-QOL) is a relevant and quantifiable outcome of
care. We implemented HR-QOL assessment at all primary care visits at UCSD Owen Clinic using
EQ-5D. The study aim was to estimate the prognostic value of EQ-5D for survival, hospitalization,
and emergency department (ED) utilization after controlling for CD4 and HIV plasma viral load
(pVL).
Methods: We conducted a retrospective analysis of HIV clinic based cohort (1996–2000). The
EQ-5D includes single item measures of: mobility, self-care, usual activities, pain/discomfort, and
anxiety/depression. Each item is coded using 3-levels (1 = no problems; 2 = some problems; 3 =
severe problems). The instrument includes a global rating of current health using a visual analog
scale (VAS) ranging from 0 (worst imaginable) to 100 (best imaginable). An additional single item
measure of health change (better, much the same, worse) was included. A predicted VAS (pVAS)
was estimated by regressing the 5 EQ-5D health states on VAS using reference cell coding of health
states and random effects linear models. Survival models were fit using Cox modelling.
Hospitalization and ED rate models were estimated using population-averaged Poisson models.
Results: 965 patients met eligibility criteria. 12% were female; 42% were non-white. Median time-
at-risk was 1.2 years. Median CD4 was 233. Median log10(pVL) was 4.6. 47 deaths occurred. In two
Cox models controlling for CD4 and pVL, the adjusted hazard ratios (aHR) for VAS and pVAS as
time-varying covariates were 0.73 (95% CI: 0.63–0.83) and 0.66 (95% CI: 0.56–0.77) respectively,
for every 10 point increase in (p)VAS rating. In Poisson regression models predicting ED visit rates
and hospital discharge rates controlling for current CD4 and pVL, each of the EQ-5D health
dimensions, VAS, and health change items were significantly (p < 0.05) associated with the
outcomes. For ED visit rates, the adjusted incidence rate ratios (aIRR) were 0.86 (0.83–0.89) and
0.79 (0.75–0.82) for VAS and pVAS, respectively. For hospital discharge rates, the aIRR's were 0.85
(0.82–0.88) and 0.79 (0.75–0.82) for VAS and pVAS, respectively.
Conclusion: EQ-5D is a brief and prognostically useful predictor of mortality, hospitalization, and
ED utilization among adults under care for HIV infection, even after adjusting for CD4 and HIV
plasma viral load.
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Background
Self-reported measures of health related quality of life
(HR-QOL) and functional status have been widely incor-
porated in clinical trials and observational cohort studies
but are infrequently included among measures routinely
administered as part of primary care for patients with HIV
infection. In 1996, we implemented routine assessment of
HR-QOL using the EuroQol (EQ-5D) instrument at all
urgent and routine visits to the UCSD Owen Clinic, a
multidisciplinary adult HIV clinic. The EQ-5D is a brief,
standardized, generic measure of HR-QOL that provides a
profile of patient function and a global health state rat-
ing[1]. Previous work from the HIV Cost and Services Uti-
lization Study (HCSUS) showed that a different measure
of physical HR-QOL was prognostic for survival after
adjustment for stage of HIV disease and CD4+ lym-
phocyte count[2]. The 27-item HCSUS HR-QOL instru-
ment measured seven domains (physical functioning, role
functioning, bodily pain, general health perceptions,
emotional well-being, social functioning, and energy). We
chose the EQ-5D because of its brevity, acceptability for
routine and repetitive administration, and suitability for
cost-utility studies both in HIV-infected patients and in
patient populations with other disease conditions. We
examined the longitudinal pattern of EQ-5D responses in
our dynamic HIV health care cohort to assess its prognos-
tic value for survival and measures of health care utiliza-
tion. The primary study aim was to estimate the
prognostic value of EQ-5D for survival, hospitalization,
and emergency department (ED) utilization after control-
ling for CD4+ lymphocyte count and HIV plasma viral
load. Secondary aims were: (1) to estimate the percent,
and stability with repeated administration, of variance in
the EQ-5D global health ratings (VAS) explained by
responses to the five EQ-5D health dimensions; and (2) to
validate previous observations that EQ-5D VAS can dis-
criminate HIV-infected patients by disease severity.
Methods
We conducted a retrospective analysis of a cohort of adults
under care for HIV infection at the UCSD Owen Clinic
between 1996–2000. Patients were eligible for inclusion if
they had confirmed HIV infection and one or more pri-
mary care visits at the study clinic during the study period.
The principal study measures were longitudinal responses
to the EQ-5D and to an additional single item measure of
health change. The instrument was administered by med-
ical assistants at the time of clinic check-in following the
recording of vital signs. Study covariates were docu-
mented in a longitudinal electronic medical record and
included socio-demographic characteristics, CD4+ lym-
phocyte counts, HIV plasma viral load (Roche Amplicor
HIV-1 Monitor), hospitalizations, emergency department
visits, and mortality verified by search of the Social Secu-
rity death index. EQ-5D includes single item measures of
five health dimensions: mobility, self-care, usual activi-
ties, pain/discomfort, and anxiety/depression. Each item
has three possible response options that allow the patient
to ordinally (no problems/some or moderate problems/
extreme problems) rate their current state with respect to
each of the 5 domains. In addition, EQ-5D includes a glo-
bal rating of current health using a visual analog scale
(VAS) ranging from 0 (worst imaginable) to 100 (best
imaginable). We also included a separate single item
measure of health change (better, much the same, worse)
compared to the prior year.
For each eligible patient, analysis time began with the first
visit to the Owen Clinic or on 1 January 1996 for those
with visits prior to that date. Analysis time was divided
into six month intervals by calendar year. For each six
month period in which a patient had more than one visit,
median values of VAS and the five EQ-5D health dimen-
sions were assigned. Similarly, for each six month period,
median values of CD4+ lymphocyte count and log10-
transformed HIV plasma viral load were assigned for each
patient. The number of hospital admissions and number
of emergency department visits for each patient were sep-
arately summed by half year. The date of death was
assigned according to adjudication by the study clinician
(WCM) of death dates from two sources: a clinic registry
and the Social Security death index. For analyses pertain-
ing to survival, follow up times end on the death date with
censoring of remaining patients on the earlier of the date
of the last encounter at the study medical center or the end
of the study period (30 June 2000). For analyses pertain-
ing to hospital discharges and emergency department uti-
lization, follow up ended on the date of the last encounter
at the study medical center or the end of the study period
(30 June 2000). For half years in which no encounters at
the study medical center were documented, patients were
not considered to be at risk for study outcomes by using
discontinuous intervals of risk[3]. As a result, patients
contribute only those half years to the analysis in which
they had at least one clinic visit.
To estimate the percent variance of VAS explained by
responses (R2) to the five EQ-5D health dimensions, VAS
was regressed on the five reference cell coded [4] EQ-5D
health dimensions. This analysis was conducted sepa-
rately for the first five half years of follow up to determine
if variance explained decayed with repeated administra-
tion of EQ-5D.
To estimate the criterion-related validity of EQ-5D VAS
when compared with CD4+ lymphocyte count and HIV
plasma viral load, we compared, for the first half year
measurement, median VAS scores across categories of
CD4+ lymphocyte count (<50, 50–199, ≥ 200 cells/mm3)
using a Kruskal Wallis test and compared median VASHealth and Quality of Life Outcomes 2007, 5:5 http://www.hqlo.com/content/5/1/5
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scores across categories of HIV plasma viral load (< 1,000,
≥ 1,000 copies/mL) using a Wilcoxon rank sum test. We
also report receiver operating characteristic (ROC) curve
area[5] for EQ-5D VAS as test measure and, as criterion
measures, binary coded CD4+ lymphocyte count (<50,
≥50) and plasma viral load (< 1,000, ≥ 1,000 copies/mL).
The values of these ROC curve areas represent a measure
of how well the VAS can discriminate between low and
high values (<50, ≥50) of CD4+ lymphocyte count and
between low and high (< 1,000, ≥ 1,000) values of viral
load. Values for the areas close to one indicate excellent
ability to discriminate, whereas values close to 0.50 indi-
cate close to chance ability to discriminate between the
groups.
A predicted VAS (pVAS) was estimated in a random effects
linear regression model[6] by regressing the five EQ-5D
health states on VAS using indicator coding of the health
states. These random effects linear regression models
allow for a different intercept for each patient, and the
intercepts are assumed to be normally distributed. pVAS
may be interpreted as a weighted average of the 5 health
dimension scores summarized in a single metric. Survival
models which model time to death were fit using Cox
modelling incorporating EQ-5D, CD4 count, and HIV
plasma viral load as time-varying covariates. It was con-
firmed that the proportional hazards assumption was met
for all covariates included in the Cox models using log(t)
by covariates interactions[7]. Hospitalization and ED rate
Poisson regression models were estimated using popula-
tion-averaged generalized estimating equations
(GEE)[8,9] with the same time varying covariates. Gener-
alized estimating equation models carry fewer assump-
tions than other parametric models and focus on
marginal effects. Opposite to random effects models
where estimated effects of covariates are conditional on
subject-specific effects, in a GEE model they relate to
effects averaged over individuals. For half years in which
no CD4 or viral load was recorded but during which one
or more medical encounters occurred at the medical
center, the last observation on these laboratory measures
was carried forward. The modelling approach for each of
the three dependent variables (survival, hospital dis-
charges, and emergency department visits) was to exam-
ine CD4 and viral load jointly-adjusted effects of each EQ-
5D health dimension, VAS, pVAS, and the health change
item. Effects are presented as adjusted hazard ratios (aHR)
for time to death and as adjusted incidence rate ratios
(aIRR) for ED utilization and hospitalization. It should be
noted that although these models examine the adjusted
effects of each predictor taken one at a time, the model
including pVAS may be interpreted to reflect the joint
effect of the five EQ-5D health dimensions summarized as
their weighted average. CD4 count was modelled as a time
varying covariate using reference cell coding for 3 catego-
ries (<50, 50–199, ≥ 200). Similarly, HIV viral load was
modelled as a time varying covariate with 2 categories (<
1000,  ≥ 1000 copies/ml). Tests of significance are not
adjusted for multiple comparisons. Statistical analyses
were performed using Stata 9.2 (Stata Corporation, Col-
lege Station, TX). This research was approved by the Uni-
versity of California San Diego Human Subjects
Committee (Project No. 040394).
Results
Between January 1996 – June 2000, 965 patients met eli-
gibility criteria (Table 1). The study population was pre-
dominantly male (88%) with HIV transmission risk factor
men having sex with men (59%) and antiretroviral ther-
apy experienced (59%). By race/ethnicity, 34% were
either Black or Hispanic. Median absolute CD4 and log10-
HIV plasma viral load were 233 and 4.6, respectively.
Median time at risk was 1.2 years. The median number of
half years in which at least one EQ-5D score was docu-
mented was 3 (range: 1–9). Forty seven deaths occurred
over the 4.5 year study period. Cumulatively over the
study period, the percent of patients with 0, 1, and ≥2
emergency department visits was 60%, 24%, and 16%,
respectively. The percent of patients with 0, 1, and ≥ 2
admissions was 61%, 23%, and 16%, respectively.
Variance explained analyses
The variance in VAS scores explained (R2) by the five indi-
cator coded EQ-5D health dimensions over the first five
half-years of observations was: 39% (n = 915), 47% (n =
735), 48% (n = 511), 56% (n = 348), and 55% (n = 248),
respectively. The stability of these estimates with extended
follow up suggests that there was no appreciable decay in
the meaningfulness of patient responses with repeated
administration of the instrument.
Criterion related validity
Median EQ-5D VAS scores for the first half year measure-
ment period varied significantly by CD4+ lymphocyte cat-
egory (see Figure 1) and were borderline significant by
HIV plasma viral load. Median EQ-5D VAS scores were
64.5, 70, and 75 for CD4 < 50, 50–199, ≥ 200 cells/mm3,
respectively (Kruskal Wallis χ2 (2 d.f.) = 28.0, p = 0.001).
ROC area for the CD4 criterion (<50, ≥ 50 cells/mm3) was
0.614 (95% CI: 0.566 – 0.662). Median VAS scores were
70 and 75.5 for plasma viral load categories ≥ 1000 and <
1000 copies/mL, respectively (Wilcoxon rank sum z =
1.90, p = 0.057. ROC area for the same plasma viral load
criteria was 0.555 (95% CI: 0.506 – 0.604).
Survival outcome
Table 2 presents CD4 and plasma viral load adjusted
effects of each EQ-5D health dimension score, VAS, pVAS,
and health change on mortality. Each covariate except
anxiety/depression was significantly associated with mor-Health and Quality of Life Outcomes 2007, 5:5 http://www.hqlo.com/content/5/1/5
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tality with evidence of a "dose-response" relationship for
increasing scores on each of the 4 remaining EQ-5D
health dimensions and on the health change item. In
addition, higher scores on VAS and on the weighted aver-
age of the five EQ-5D health dimensions (pVAS) was sig-
nificantly (p < 0.05) predictive of survival, with adjusted
hazard ratios (aHR) for death of 0.73 and 0.66, respec-
tively. In two separate Cox models of time to death that
adjusted simultaneously for CD4+ lymphocyte category,
plasma viral load, and either VAS or pVAS, the additional
health change item had no independent effect (p = 0.14
and p = 0.14, respectively). Of note, some of the confi-
dence intervals are relatively wide due to a combination of
two aspects: 1) Some categories are reported rarely (e.g.
unable to wash or dress for self care) and 2) The outcome
(death) is relatively rare (47 of all patients with EQ-5D
data).
Emergency department utilization outcome
Each of the examined covariates was significantly (p <
0.05) associated with emergency department utilization,
but the relationships were more complex than those
observed for the survival outcome (Table 3). For mobility
and self-care, those with "some problems" demonstrated
approximately twice the utilization of those with either
"no problems" or those who were either confined to bed
or unable to wash/dress. Higher scores on the pain item
were incrementally predictive of higher visit rates (aIRR
1.7moderate, 2.7extreme) and those with "extreme" anxiety or
depression had higher (aIRR 2.0) emergency utilization
than those with no reported anxiety or depression. Higher
scores on VAS and pVAS, both reflecting better overall
health, were associated with lower emergency department
visit rates. Finally, those rating their current health as
worse than a year previously had nearly twice the rate of
ED utilization than those rating their health as better or as
unchanged. In two separate models of ED utilization that
adjusted simultaneously for CD4+ lymphocyte category,
plasma viral load, and either VAS or pVAS, the additional
health change item was independently predictive of the
outcome (p = 0.003 and p = 0.02, respectively).
Hospital discharge rate outcome
For the hospitalization rate outcome (Table 4), each of the
examined covariates was predictive. Those with the high-
est scores on mobility, self-care, usual activities, and pain/
discomfort had 2.3 to 3.5 times the rates of hospitaliza-
tion than those with no impairment in those health
dimensions. Those with extreme anxiety or depression
had a 50% higher rate than those with no anxiety or
depression. Both global health indicators (VAS and pVAS)
showed significant relationships in the predicted direc-
tion with hospitalization with adjusted aIRRs of 0.85 and
0.79, respectively. Those who rated their current health as
worse than a year previously had twice the hospitalization
rate of those who rated it as better. In two separate models
of hospitalization rate that adjusted simultaneously for
CD4+ lymphocyte category, plasma viral load, and either
VAS or pVAS, the additional health change item was inde-
pendently predictive of the outcome when VAS was
included (p = 0.02), but not when pVAS was included (p
= 0.09).
Discussion
This study has demonstrated that a brief, non-disease spe-
cific measure of health related quality of life, when
Table 1: Baseline Characteristics of Cohort (n = 965)
Characteristic Distribution
Sex [n (%)]
Female 117 (12%)
Male 848 (88%)
Age [mean (range)] 37 (18 – 67)
Transmission Risk Factor [n (%)]
MSM, not IDU 567 (59)
IDU 189 (20)
Heterosexual 160 (17)
Other/Unknown 49 (5)
Race/Ethnicity [n (%)]
Black 139 (14)
Hispanic 193 (20)
White 559 (58)
Other/Unknown 74 (8)
Prior Antiretroviral Treatment [n (%)]
Experienced 571 (59)
Naive 394 (41)
Absolute CD4 [mean (std dev)] 233 (337)
log10 HIV Plasma Viral Load [mean (std dev)] 4.6 (1.7)Health and Quality of Life Outcomes 2007, 5:5 http://www.hqlo.com/content/5/1/5
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administered routinely to adults under care for HIV infec-
tion, captures prognostic information independent of cur-
rent CD4+ lymphocyte count and HIV plasma viral load.
In addition, we confirmed previous observations[10] that
the EQ-5D VAS score has the potential to discriminate
among patients varying in CD4+ lymphocyte count. The
EQ-5D also has high acceptability in a busy HIV clinic,
even when administered at every routine clinic visit by
medical assistants as part of vital sign documentation.
Meaningfulness of patient responses on repeat adminis-
tration seems not to decay when assessed by variance in
VAS scores explained by responses on the EQ-5D health
dimensions.
HR-QOL is a multidimensional construct, the compo-
nents of which have been conceptualized as encompass-
ing physiological factors, symptom status, functional
health, general health perceptions, and overall quality of
life[11] and this conceptual model has received some
empirical validation recently in a retrospective analysis of
an HIV health care cohort[12]. There have been a number
of reviews since the early 1990s of HR-QOL measures
administered to patients with HIV infection, and no con-
sensus has emerged on a clearly preferred instrument for
use either in clinical trials or in clinical care [13-20]. How-
ever, a number of both disease-specific and generic meas-
ures have been advocated for use in specific populations
and settings. The most well validated ones have been
reviewed most recently by Clayson et al[13] who among
generic measures considered the EQ-5D, Health Utilities
Index (HUI), and SF-36, and among HIV-specific meas-
ures, reviewed the following six measures: Medical Out-
comes Study HIV Health Survey (MOS-HIV), Functional
Assessment of HIV Infection (FAHI), Multidimensional
QOL for Persons Living with HIV/AIDS (MQoL-HIV),
HIV/AIDS-Targeted Quality of Life Instrument (HAT-
EQ-5D VAS Distribution by CD4 Category (1st half year median VAS score for each patient) Figure 1
EQ-5D VAS Distribution by CD4 Category (1st half year median VAS score for each patient).
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QoL), Living With HIV Scale (LWH), and General Health
Self-Assessment (GHSA). These nine instruments were
reviewed for possible use in clinical trials on the basis of
four review criteria: (1) content validity for physical func-
tion, social/role function and mental health/emotional
well-being, (2) practicality (self administered taking ≤ 15
minutes with ≤ 50 items), (3) psychometric properties
(dimensionality, reliability, validity, and responsiveness),
and (4) the availability of normative data and/or popula-
tion-based preference weights. Clayson and co-workers
concluded that, although there is no one best HR-QOL
measure for use in HIV/AIDS clinical trials, three generic
(EQ-5D, SF-36, HUI) and two HIV-targeted candidate
measures (FAHI, MOS-HIV) appear to be more favorable
than others for consideration.
Responses to the five EQ-5D health dimensions define
243 possible health states for which general population
preference weights have been derived for U.S., European,
Japanese, and African samples. The population-specific
preference weights for EQ-5D health states can be trans-
formed into summary index scores (EQ-5Dindex) suitable
for use in cost-utility studies. In a cross sectional study of
a sample of HIV-infected patients, Delate and Coons dem-
onstrated that EQ-5D health index scores and VAS dis-
criminated between patients with CD4 ≤ 200 cells/mm3
and CD4>200 cells/mm3 and between those with HIV
plasma viral load ≤ 30,000 copies/mL and > 30,000 cop-
ies/mL[10]. In an AIDS clinical trial setting with all
patients entering with CD4<100 cells/mm3, Wu et al.
demonstrated that both the EQ-5D Index and EuroQol
VAS correlated with MOS-HIV mental health and physical
health summary scores[21]. In the same study, the inves-
tigators evaluated the responsiveness of EQ-5D to the
development of adverse events (AEs) and opportunistic
infections (OI) during the trial. The EQ-5D was less
responsive than MOS-HIV pain and physical health scores
to AEs. However, the EuroQol VAS was more responsive
to OI induced change than the MOS-HIV physical health
score. In a previous study of the UCSD Owen Clinic
Table 2: CD4 and Viral Load Adjusted Hazard Ratios (HR) of EQ-5D and Health Change in Cox Model of Survival
Measure1 Half yrs/n/deaths2 Adjusted4
HR 95% CI p-value
Mobility 3006/953/47 <0.001
No problems 1908/./4 1.0
Some problems 1052/./36 10.0 3.5–28.4 <0.001
Confined to bed 46/./7 27.0 7.7–94.9 <0.001
Self-Care 3007/954/47 <0.001
No problems 2421/./13 1.0
Some problems 547/./26 5.0 2.5–10.0 <0.001
Unable to wash or dress 39/./8 14.1 5.5–36.0 <0.001
Usual Activities 3008/954/47 <0.001
No problems 1638/./5 1.0
Some problems 1249/./27 4.3 1.6–11.3 <0.001
Unable to perform 121/./15 17.3 6.1–49.4 <0.001
Pain/Discomfort 3007/954/45 0.001
None 1085/./3 1.0
Moderate 1609/./26 3.7 1.1–12.4 0.032
Extreme 313/./16 10.9 3.1–37.6 <0.001
Anxiety/Depression 3005/954/46 0.086
None 1389/./14 1.0
Moderate 1365/./25 1.5 0.8–2.9 0.22
Extreme 251/./7 2.8 1.1–7.1 0.028
VAS3 (per 10 units) 2987/950/44 0.73 0.63–0.83 <0.001
pVAS (per 10 units) 2994/948/45 0.66 0.56–0.77 <0.001
Health change 3006/955/46 <0.001
Better 761/./5 1.0
Much the same 1722/./15 1.2 0.4–3.3 0.74
Worse 523/./26 4.6 1.7–12.2 0.002
1. Items 1–5 (Mobility, Self Care, Usual Activities, Pain/Discomfort, Anxiety/Depression) are EQ-5D health states. Health change is not part of EQ-
5D. EQ-5D health states, VAS, health change, CD4 category, and HIV-1 plasma viral load are modelled as time-varying covariates.
2. Number of half years/number of patients/number of deaths. Note, the number of patients is not provided for individual categories as half years 
from the same patient can occur in multiple categories.
3. EQ-5D Visual Analog Scale (VAS) rating of global health status (0–100); pVAS (predicted VAS; see Methods)
4. Each covariate is adjusted only for CD4 category (<50, 50–199, ≥200) and plasma HIV-1 viral load (<1,000, ≥1,000 copies), not for the other 
listed health status items. CD4 category and plasma HIV-1 viral load are modelled as time-varying covariates.Health and Quality of Life Outcomes 2007, 5:5 http://www.hqlo.com/content/5/1/5
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cohort, we observed, in a sample with median CD4 = 117
cells/mm3, that scores on five EQ-5D health dimensions
explained 46% of the variance in the patients' concomi-
tant VAS ratings. Of the possible 243 possible EQ-5D
health states, 83 were observed in the patient sample of
530[22].
A global single item rating of health change such as was
included in this study is one type of an anchor-based
method for determining health change. Such measures
have the advantages that they are easy to ascertain and
take into account a variety of information from the
patient's perspective. However, like all single item meas-
ures, they may have limited precision and reliability and
may yield varying results when current health is compared
to other anchor states[23]. Studies have shown that
responses to global health transition items may be dispro-
portionately influenced by the current health state and
may not adequately incorporate their state at the reference
time point[24,25]. Nonetheless, health transition items
may complement and at times be more sensitive to
change than multi-item measures of current health
state[26]. The addition of a single item health change
measure in our study was shown to contribute independ-
ent prognostic information when compared to the Euro-
Qol VAS and pVAS. Future analyses of the dataset will
explore whether changes in sequential EQ-5D responses
are correlated with patients' retrospective global assess-
ment of health change. These future analyses will also
contribute to an examination of whether the EQ-5D is
subject to a "ceiling effect" in this population, a phenom-
enon that limits the ability to detect change when baseline
scores are high and which has been reported when EQ-5D
has been used in general population studies[27].
Inference from this research is subject to a number of lim-
itations. First, although assessment of the mortality out-
come is robust, there may have been some
hospitalizations and ED visits outside our health care sys-
tem that were not captured in our data sources. We believe
that this outside utilization to be minor because the study
medical center is the primary referral center for HIV care
Table 3: CD4 and Viral Load Adjusted Incidence Rate Ratios (IRRs) for Emergency Department Visit Rate in Poisson Models
Measure1 Adjusted3
IRR 95% CI p-value
1. Mobility <0.001
No problems 1.0
Some problems 2.0 1.7–2.3 <0.001
Confined to bed 1.0 0.6–1.8 0.90
2. Self-Care <0.001
No problems 1.0
Some problems 1.9 1.6–2.2 <0.001
Unable to wash or dress 1.2 0.7–1.9 0.56
3. Usual Activities <0.001
No problems 1.0
Some problems 1.8 1.5–2.1 <0.001
Unable to perform 1.9 1.5–2.6 <0.001
4. Pain/Discomfort <0.001
None 1.0
Moderate 1.7 1.5–2.1 <0.001
Extreme 2.7 2.2–3.4 <0.001
5. Anxiety/Depression <0.001
None 1.0
Moderate 1.6 1.4–1.9 <0.001
Extreme 2.0 1.6–2.5 <0.001
VAS2 (per 10 units) 0.86 0.83–0.89 <0.001
pVAS (per 10 units) 0.79 0.75–0.82 <0.001
Health change <0.001
Better 1.0
Much the same 1.1 0.9–1.3 0.30
Worse 1.9 1.5–2.3 <0.001
1. Items 1–5 (Mobility, Self Care, Usual Activities, Pain/Discomfort, Anxiety/Depression) are EQ-5D health states. Health change is not part of EQ-
5D. EQ-5D health states, VAS, health change, CD4 category, and HIV-1 plasma viral load are modelled as time-varying covariates.
2. EQ-5D Visual Analog Scale (VAS) rating of global health status (0–100); pVAS (predicted VAS; see Methods)
3. Each covariate is adjusted only for CD4 category (<50, 50–199, ≥200) and plasma HIV-1 viral load (<1,000, ≥1,000 copies), not for the other 
listed health status items. CD4 category and plasma HIV-1 viral load are modelled as time-varying covariates.Health and Quality of Life Outcomes 2007, 5:5 http://www.hqlo.com/content/5/1/5
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in the civilian and public sectors in San Diego. Second,
although it is clinic policy to administer the EQ-5D at all
primary care and urgent visits, when patients come in
severely ill, the survey may not be administered. This bias
would tend to attenuate an association between EQ-5D
scores and morbid outcomes, but our analysis nonethe-
less showed easily detectable effects for all three outcome
measures. Third, previous evaluations of EQ-5D have
used raw scores as the unit of analysis. Our study averaged
scores over calendar half years in order to provide more
stable estimates of health status within half year periods.
We acknowledge that this approach may limit the compa-
rability of the findings to studies using individual admin-
istrations of EQ-5D as the unit of analysis. Fourth,
because of the averaging of scores within half years, there
is some temporal ambiguity in interpreting possible
causal associations between EQ-5D scores and the rates of
ED use and hospitalization. That is, within a given half
year, some of the EQ-5D scores were ascertained after an
outcome event had taken place and could not therefore be
considered predictive of an antecedent outcome. On the
other hand, to the extent that events occurred in future
half years, a predictive association would be validly dem-
onstrated. This is not a limitation for the mortality out-
come.
Conclusion
Despite these limitations, we conclude that both the EQ-
5D and health change item contribute meaningful prog-
nostic information for three important health care out-
comes for adults under care for HIV infection. The
prognostic value of these measures will be of use in epide-
miological studies but not necessarily evident in predic-
tion of individual patient outcomes. The research has
confirmed previous support for the criterion-related valid-
ity of EQ-5D when assessed in relation to CD4+ lym-
phocyte category and plasma viral load. Finally, we have
some confidence that repeated administration of the
instrument in a clinical care setting does not result in
decay of the meaningfulness of responses when assessed
using a criterion of percent variance explained.
Table 4: CD4 and Viral Load Adjusted Incidence Rate Ratios (IRRs) for Hospital Discharge Rate in Poisson Models
Measure1 Adjusted3
IRR 95% CI p-value
Mobility <0.001
No problems 1.0
Some problems 2.3 2.0–2.8 <0.001
Confined to bed 2.9 2.1–4.0 <0.001
Self-Care <0.001
No problems 1.0
Some problems 2.1 1.8–2.4 <0.001
Unable to wash or dress 2.3 1.7–3.2 <0.001
Usual Activities <0.001
No problems 1.0
Some problems 2.2 1.9–2.7 <0.001
Unable to perform 3.5 2.7–4.5 <0.001
Pain/Discomfort <0.001
None 1.0
Moderate 1.9 1.6–2.3 <0.001
Extreme 3.1 2.4–3.9 <0.001
Anxiety/Depression 0.01
None 1.0
Moderate 1.1 0.9–1.3 0.31
Extreme 1.4 1.1–1.8 0.002
VAS2 (per 10 units) 0.85 0.82–0.88 <0.001
pVAS (per 10 units) 0.79 0.75–0.82 <0.001
Health change <0.001
Better 1.0
Much the same 1.2 1.0–1.5 0.032
Worse 2.0 1.6–2.5 <0.001
1. Items 1–5 (Mobility, Self Care, Usual Activities, Pain/Discomfort, Anxiety/Depression) are EQ-5D health states. Health change is not part of EQ-
5D. EQ-5D health states, VAS, health change, CD4 category, and HIV-1 plasma viral load are modelled as time-varying covariates.
2. EQ-5D Visual Analog Scale (VAS) rating of global health status (0–100); pVAS (predicted VAS; see Methods)
3. Each covariate is adjusted only for CD4 category (<50, 50–199, ≥200) and plasma HIV-1 viral load (<1,000, ≥1,000 copies), not for the other 
listed health status items. CD4 category and plasma HIV-1 viral load are modelled as time-varying covariates.Publish with BioMed Central    and   every 
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